Disruptive innovation in breast cancer therapeutic development

Area of Science:

• Biotechnology
• Oncology
• Health Services Research

Background:

• Therapeutic development is inherently disruptive, with varying degrees of success.
• Understanding innovation frameworks is crucial for analyzing therapeutic performance.

Purpose of the Study:

• To analyze therapeutic development using Christensen's disruptive innovation framework.
• To identify factors contributing to the underperformance of mutation-anchored agents.
• To explore the potential of host-driven, subtype-agnostic modalities for scalable impact.

Main Methods:

• Application of Christensen's disruptive innovation framework.
• Analysis of therapeutic agent performance based on targeting strategy (mutation-anchored vs. broadly acting).
• Evaluation of host-driven, subtype-agnostic modalities (immunotherapy, antibody-drug conjugates, cell and gene therapies).

Main Results:

• Mutation-anchored agents sometimes underperform due to their specific targeting.
• Broadly acting therapies demonstrate success as disruptive therapies.
• Host-driven, subtype-agnostic modalities present a model for scalable and durable impact.

Conclusions:

• Host-driven, subtype-agnostic therapies represent a disruptive innovation in medicine.
• These modalities offer a strategic blueprint for achieving significant clinical and commercial success.
• The disruptive innovation framework provides valuable insights into therapeutic development strategies.